Akebia develops and sells kidney disease medicines, including the anemia treatment Vafseo and the phosphorus control drug Auryxia. It last closed at $0.40 on Nov 17, down 10.74% on the day. The average 12-month price target from 4 analysts is $3.38 (+742.9% from the last close), with a high of $4.50 and a low of $2.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Each firm's latest rating on AKBA in the past 90 days
Average 12-month target
$3.38
▲ 742.9% upside
Based on 4 analysts who set a price target on AKBA in the past 90 days. The average target is $3.38, with a high of $4.50 and a low of $2.00, compared with the last close of $0.40.
Low $2.00Avg $3.38High $4.50
Blue marker: last close $0.40
Highest target$4.50
Average target$3.38
Lowest target$2.00
Latest rating changes
Piper SandlerMaintained
Nov 16Buy$2
HC Wainwright & Co.Target lowered
Nov 6Buy$6 → $4
BTIGMaintained
Nov 5Buy$3
WestPark CapitalInitiated
Sep 8Buy$4.50
Leerink PartnersDowngrade
Aug 8Hold$1
Date
Firm
Action
Rating
Price target
Nov 16
Piper Sandler
Maintained
Buy
$2
Nov 6
HC Wainwright & Co.
Target lowered
Buy
$6 → $4
Nov 5
BTIG
Maintained
Buy
$3
Sep 8
WestPark Capital
Initiated
Buy
$4.50
Aug 8
Leerink Partners
Downgrade
Hold
$1
Loading…
Technical Analysis
AKBA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 46% below its 20 day and 87% below its 50 day average. It is 173% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $0.38, and the nearest resistance the Pivot at $0.41.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 17.8%/day
Key levels
$1.8452 week high+360.0%
$1.09200 day average+172.5%
$0.94100 day average+135.0%
$0.7550 day average+87.5%
$0.5820 day average+45.0%
$0.58Swing high (Nov 11)+45.0%
$0.44Pivot R1+10.0%
$0.41Pivot+2.5%
$0.40Last close
$0.38Pivot S1−5.0%
$0.3652 week low−10.0%
$0.36Swing low (Nov 6)−10.0%
Indicators
RSI (14)
32.46
Weak, oversold below 30
Neutral
MACD
-0.09
Below its signal line
Bearish
Stochastic
18.2
Near the bottom of its range
Oversold
ADX (14)
27.3
Trending down
Williams %R
-91.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-116.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−44.8%
Change over 10 sessions
Bearish
ATR (14)
$0.07
Typical daily range, 17.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 44.2%/day
Key levels
$1.8452 week high+360.0%
$1.09200 day average+172.5%
$0.94100 day average+135.0%
$0.7550 day average+87.5%
$0.5820 day average+45.0%
$0.58Swing high (Nov 11)+45.0%
$0.44Pivot R1+10.0%
$0.41Pivot+2.5%
$0.40Last close
$0.38Pivot S1−5.0%
$0.3652 week low−10.0%
$0.36Swing low (Nov 6)−10.0%
Indicators
RSI (14)
30.58
Weak, oversold below 30
Neutral
MACD
-0.21
Below its signal line
Bearish
Stochastic
8.7
Near the bottom of its range
Oversold
ADX (14)
27.4
Trending down
Williams %R
-94.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-154.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−57.9%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 44.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AKBA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how AKBA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow AKBA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AKBA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKBA is in one of them and how their past AKBA trades turned out.
Akebia is a biopharmaceutical company based in Waltham, Massachusetts, that develops and sells medicines for people with kidney disease. Its main product, Vafseo, is an oral treatment for anemia caused by chronic kidney disease in adults on dialysis. Its second product, Auryxia, is an oral medicine used to control phosphorus levels in dialysis patients and to treat iron deficiency anemia in adults with kidney disease who are not on dialysis. The company also develops treatments for rare kidney conditions.